Evaluation and analysis of exposure levels of di(2-ethylhexyl) phthalate from blood bags

Abstract

Background The US FDA and The Ministry of Health, Labor and Welfare of Japan have indicated that the risk assessment of di(2-ethylhexyl) phthalate (DEHP) released from polyvinyl chloride (PVC) medical devices requires immediate attention. In particular, the analysis of the exposure to DEHP from blood bags is very important for medical treatment. However, human exposure to DEHP via blood transfusion remains poorly understood. We evaluated DEHP and mono(2-ethylhexyl) phthalate (MEHP) levels, migration patterns, and metabolism in blood products for the detailed assessment of exposure to DEHP. Methods A method that is based on column-switching liquid chromatography–electrospray mass spectrometry (LC–MS) coupled with on-line extraction was used for the direct analysis of DEHP and MEHP in the blood products. From the Japanese Red Cross Society, 78 blood products (red blood cell concentrate: n = 18, irradiated red blood cell concentrate: n = 18, whole blood: n = 18, blood platelet: n = 18, and frozen plasma: n = 6) were sampled in January 2003 for use in this study. Results The detection levels of DEHP and MEHP ranged from 1.8 to 83.2 μg/ml and from 0.1 to 9.7 μg/ml, respectively. The levels of MEHP and DEHP in the blood products were increased with increasing storage time. In addition, whole blood products in PVC bags had the highest DEHP levels compared to the other blood products. Our results indicate that the maximum level of human exposure to DEHP released from blood bags is 0.7 mg/kg weight/time. Conclusion This first quantitative evidence may be useful for the risk assessment of DEHP released from blood bags.